Total Funding
52
55
Total FundingPost-IPO Equity raised
Growth Score
-21 pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
61878
INmune Bio is developing therapies that harness the patient’s immune system to treat cancer.
- David Moss: President & CEOPast Role: INmuneBIO, CFO
- Cory Ellspermann: Interim CFOPast Role: INmuneBIO, Controller and VP of Finance
About the Company
INmune Bio is a clinical-stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer.
INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer
relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
